Can a New Ultra-Long-Acting Insulin Analogue Improve Patient Care? Investigating the Potential Role of Insulin Degludec Jennifer D. RobinsonJoshua J. NeumillerR. Keith Campbell Current Opinion 26 December 2012 Pages: 2319 - 2325
US Food and Drug Administration’s Risk Evaluation and Mitigation Strategy for Extended-Release and Long-Acting Opioids Sebastiano MercadanteDavid CraigAntonello Giarratano Current Opinion 26 December 2012 Pages: 2327 - 2332
Diagnosis and Therapeutic Management of Extra-Intestinal Manifestations of Inflammatory Bowel Disease Guru TrikudanathanPreethi G. K. VenkateshUdayakumar Navaneethan Review Article 26 December 2012 Pages: 2333 - 2349
Optimal Use of Treprostinil in Pulmonary Arterial Hypertension Nika Skoro-Sajer Review Article 26 December 2012 Pages: 2351 - 2363
Primary Prevention of Major Cardiovascular and Cerebrovascular Events with Statins in Diabetic Patients Folgerdiena M. de VriesPetra DenigEelko Hak Systematic Review 26 December 2012 Pages: 2365 - 2373
Ingenol Mebutate Gel 0.015% and 0.05% Gillian M. Keating Adis Drug Profile 26 December 2012 Pages: 2397 - 2405
Meningococcal Quadrivalent (Serogroups A, C, W135 and Y) Tetanus Toxoid Conjugate Vaccine (Nimenrix™) Jamie D. CroxtallSohita Dhillon Adis Drug Evaluation 26 December 2012 Pages: 2407 - 2430